NEWSROOM

Healthcare

American Shared Hospital Services Reports First Quarter 2024 Financial Results

American Shared Hospital Services Reports First Quarter 2024 Financial Results

May 14, 2024

- Reports Record Backlog of $210 million more than doubling following the acquisition of Rhode Island Radiation Therapy Cancer Centers in May 2024 - - Remains on track with opening new Puebla, Mexico center - -Conference Call Today, May 14th at 4:30 pm ET - SAN FRANCISCO, CA, May 14, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

May 14, 2024

Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 Company Reports First Quarter EBITDA of $4.9 Million Project Continued Growth from Sales of AmnioWrap2 ® Financial Results Conference Call and Webcast on Tuesday, May 14, 2024, at 4:30 pm EDT POMPANO BEACH, FLORIDA, May 14, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived...

Oncocyte to Announce First Quarter 2024 Financial Results

Oncocyte to Announce First Quarter 2024 Financial Results

May 13, 2024

Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m. ET IRVINE, CA, May 13, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, after U.S. market close. The company will host a conference call and webcast on Wednesday, May 15, 2024, at 4:30 p.m. Eastern Time to discuss its financial results and highlights. Interested parties...

American Shared Hospital Services Reports First Quarter 2024 Financial Results

American Shared Hospital Services Announces Closing of Acquisition of 60% Majority Interest in Three Radiation Therapy Cancer Centers in Rhode Island

May 9, 2024

- Adds $9-$10 million in Annual Revenue with Positive Net Income Contribution - - Acquisition more than Doubles Backlog to over $210 million - - Expands U.S. Footprint and Product Offering - SAN FRANCISCO, CA, May 9, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy cancer treatment systems and services, today announced the closing of its acquisition of a...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

May 7, 2024

Conference Call on Tuesday, May 14th, at 4:30 pm ET POMPANO BEACH, FLORIDA, May 7, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading biotechnology company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, announced today that it plans to release its first quarter 2024 financial results post-market on Tuesday, May 14, 2024. BioStem will host a conference call and webcast at 4:30 pm ET on Tuesday, May 14, 2024. The call...

American Shared Hospital Services Reports First Quarter 2024 Financial Results

American Shared Hospital Services Announces First Quarter 2024 Earnings Conference Call

May 7, 2024

SAN FRANCISCO, CA, May 7, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a conference call to discuss its first quarter 2024 financial results on Tuesday, May 14th at 4:30 pm ET / 1:30 pm PT. The first quarter 2024 financial results press release will be issued at the market close on...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Granted Prioritized Examination for Wound Healing Patent

May 6, 2024

POMPANO BEACH, FLORIDA, May 6, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived allografts for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company’s request for Prioritized Examination for its application for U.S. Patent 18/290,914 titled STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF. “As we...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts

Apr 30, 2024

POMPANO BEACH, FLORIDA, April 30, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived tissue allografts for advanced wound care, today announced that it has retained the services of Mr. Nick McCoy, who will lead BioStem’s Diabetic Foot Ulcer (DFU) and Venous Leg Ulcer (VLU) clinical trials process as a consultant to the Company. BioStem’s clinical focus on completing these...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

Apr 29, 2024

Company’s flagship SSi Mantra surgical device has now been used in more than 1000 procedures FORT LAUDERDALE, FL, April 29, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced the successful performance of the first pyeloplasty procedure performed on an infant utilizing its flagship SSi Mantra...

PRISM MarketView – Weekly Market Report – April 26, 2024

PRISM MarketView – Weekly Market Report – April 26, 2024

Apr 26, 2024

PRISM Market Pulse: Equities Rally Amid Mixed Big Tech Earnings; Economic Shifts and Sector-Specific Highlights New York, N.Y., April 26, 2024 - PRISM MarketView - Equities were higher through the morning into midday trading as the S&P 500 and Nasdaq are set to snap their three- and four-week losing streaks. Big tech was the topic of Street-talk this week as some of the Magnificent Seven reported earnings. The reports produced mixed and opposite reactions by the Street as Tesla (TSLA)...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Present at the 2024 Planet MicroCap Showcase

Apr 25, 2024

BioStem CEO, Jason Matuszewski, will present on Wednesday, May 1, 2024, at 11.30 am PST POMPANO BEACH, FLORIDA, April 25, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 held at the Paris Hotel & Casino, in Las Vegas, NV., from April 30 - May 2 2024....

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior Exchange

Apr 24, 2024

Strategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value POMPANO BEACH, FLORIDA, April 24, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today announced the successful completion of comprehensive audits for fiscal years 2022 and 2023. This completion is a significant step in the company’s strategy to uplist to a...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations International Announces Q1 2024 Company Updates

Apr 22, 2024

Significant milestones achieved for SSi Mantra Made-in-India surgical robotic system FORT LAUDERDALE, FL, April 22, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced its Q1 2024 Company updates. As of March 31, 2024, SS Innovations has completed a total of 32 successful installations of...

PRISM MarketView – Biotech Breakfast

PRISM MarketView – Biotech Breakfast

Apr 22, 2024

Roche’s Alecensa Gets FDA Green Light; ImmunityBio Gains as PDUFA Date Approaches for Bladder Cancer Drug; Key Drug Trial Failures in 2024 New York, N.Y., April 22, 2024 - PRISM MarketView - Healthcare equities finished mostly higher after a very quiet trading session on Friday. The S&P 500 Healthcare Index closed up +0.32% versus the S&P 500 Index which lost (0.88%) and the XBI settled down (0.78%). A lack of momentum today left Roche stock up by just +0.95% following the FDA greenlit...

PRISM MarketView – Weekly Market Report

PRISM MarketView – Weekly Market Report

Apr 19, 2024

PRISM Market Pulse: Market Tumbles Amid Fed's Rate Stance; Mixed Corporate Earnings Highlight Sector Struggles New York, N.Y., April 19, 2024 - PRISM MarketView - Equities were down in the morning and into midday as the major indices remain on track to notch their third straight week of declines. Fedspeak continues to support the “higher-for-longer” narrative with no urgency to cut rates which has created further sharp outflows and investor skepticism. The Street has taken investors’ pulses in...

PRISM MarketView – Bio Investor Alert

PRISM MarketView – Bio Investor Alert

Apr 18, 2024

New York, N.Y., April 18, 2024 - PRISM MarketView - More than 83,000 new cases of bladder cancer are diagnosed in the US each year, and the illness is responsible for around 17,000 deaths annually. Urothelial carcinoma accounts for 90% of bladder cancers in the US and western Europe, and surgery, followed by chemotherapy or radiation is the current standard of care. There are 24 drugs approved by the FDA for bladder cancer, but due to invasive and life-changing surgical procedures, researchers...

American Shared Hospital Services Reports First Quarter 2024 Financial Results

American Shared Hospital Services Strengthens Senior Management Structure

Apr 18, 2024

SAN FRANCISCO, CA, April 18, 2024—American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announces changes to strengthen its senior management structure. AMS’ current Executive Chairman, Ray Stachowiak, will take on the role of Executive Chairman and Chief Executive Officer, and the Company’s President, Craig Tagawa, will become...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Apr 17, 2024

The new oncology committee will include: Jason Hafron, MD, DDS, PhD, MPH; and Pradeep Tyagi, PhD, MBA Pittsburgh, PA, April 17, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company, today announced the expansion of its Scientific Advisory Board to include oncology expertise. The new committee members are: Jason Hafron, MD, DDS, PhD, MPH, the Chief Medical Officer at Michigan Institute of Urology, and Professor of Urology at the...

PRISM MarketView – Biotech Breakfast

Apr 15, 2024

Mobile-Health Network Solutions (MNDR) IPOs; Q32 Bio Surges; EMA Concludes GLP-1 Drugs Not Associated with Suicidal Thoughts New York, N.Y., April 15, 2024 - PRISM MarketView - Healthcare equities finished lower on Friday, in line with broad declines across the market. The S&P 500 Healthcare Index closed down (1.52%) versus the S&P 500 Index which lost (1.46%) and the XBI settled down (3.43%). The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee concluded...

American Shared Hospital Services Reports First Quarter 2024 Financial Results

American Shared Hospital Services Announces the Sudden Passing of CEO, Peter Gaccione

Apr 12, 2024

SAN FRANCISCO, CA, April 12, 2024 - American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announces the sudden passing of its Chief Executive Officer, Peter Gaccione. Ray Stachowiak, Executive Chairman of American Shared Hospital Services, said, “On behalf of my colleagues at AMS, we are deeply saddened by the unexpected passing of...

Oncocyte to Announce First Quarter 2024 Financial Results

ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS

Apr 12, 2024

Conference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 12, 2024 - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023. Recent Highlights Bio-Rad Laboratories, Inc. commercial partnership for transplant monitoring IP $15.8 million in gross proceeds received from private placement offering $4.4 million and $3.8 million Q4 2023 and est. Q1 2024 cash burn, respectively...

Oncocyte to Announce First Quarter 2024 Financial Results

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Apr 11, 2024

IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company, today announced that it has entered into definitive securities purchase agreements (the “Purchase Agreements”) for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant...

Oncocyte to Announce First Quarter 2024 Financial Results

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

Apr 11, 2024

- Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, CA, April 11, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and clinical diagnostics products, for the...

SS Innovations Achieves Pediatric Milestone with First Infant Pyeloplasty Using SSi Mantra Surgical Robotic System

SS Innovations’ Flagship SSi Mantra Surgical Robotic Device Successfully Completes Telesurgery Procedures

Apr 10, 2024

First-ever telesurgery using SSi Mantra performed on an animal in India FORT LAUDERDALE, FL, April 10, 2024 - SS Innovations International, Inc. (the "Company" or "SS Innovations") (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making world class robotic surgery affordable and accessible to a global population, today announced that its SSi Mantra Surgical Robotic System has successfully completed its first-ever telesurgery procedures on an animal in India....

Oncocyte to Announce First Quarter 2024 Financial Results

ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS 

Apr 9, 2024

Conference Call and Webcast on Friday, April 12, 2024, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, April 09, 2024 - Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2023 financial results on Friday, April 12, 2024, prior to the U.S. market open. The company will host a conference call and webcast on Friday, April 12, 2024, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Apr 5, 2024

Pittsburgh, PA, April 05, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois. Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel...

PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

PRISM MarketView Features Auto Parts 4 Less in the Automotive E-Commerce Marketplace

Apr 5, 2024

New York, N.Y., April 05, 2024 - PRISM MarketView announces the release of an informative interview with Auto Parts 4 Less CEO Christopher Davenport, explaining the company’s strategic business model and focus on expanding its automotive eCommerce marketplace. Christopher Davenport - CEO of Auto Parts 4 Less Auto Parts 4 Less is an innovator focused on developing a world-class eCommerce marketplace for automotive parts that utilizes integrated technologies to optimize the listing, selling, and...

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Apr 3, 2024

Pittsburgh, PA, April 03, 2024 - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10, an intravesical liposomal formulation of tacrolimus, as a potential treatment for...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies to Present at the 14th Annual LD Micro Invitational Conference

Apr 2, 2024

BioStem CEO, Jason Matuszewski, will present on Tuesday, April 9, 2024, at 12:30 pm ET POMPANO BEACH, FLORIDA, April 2, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that it will present at the 14th Annual LD Micro Invitational Conference at the Sofitel New York on April 8-9, 2024. BioStem’s Chief Executive Officer, Jason...

BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million

BioStem Technologies Reports Fourth Quarter Revenue of $11.5 Million, 14-Fold YoY Increase

Apr 1, 2024

-Project Continued Growth from Sales of AmnioWrap2®- -Financial Results Conference Call and Webcast on Monday, April 1, 2024 at 4:30 pm EDT- POMPANO BEACH, FLORIDA, April 1, 2024—BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today reported financial results for the fourth quarter and twelve months ended December 31, 2023. Jason Matuszewski, CEO of BioStem,...